AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Rocket Pharmaceuticals, Inc.
Video analysis: RCKT
All videosNo video analysis for this stock yet. Request one from our team.
News: RCKT
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock?
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference in New York. Gaurav Shah, M.D., Chief Executive Officer, will take part in fireside chats.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of “Hold” by Analysts
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT - Get Free Report) has received a consensus rating of "Hold" from the ten analysts that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating and one has issued a strong
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps.
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today reported financial and recent operational results for the second quarter ended June 30, 2026. “The second quarter of 2026 materially strengthened Rocket's position, with the approval of KRESLADI demonstrating our ability to advance a genetic medi.
Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) on Monday shared a clinical safety update concerning the first three patients treated in its global, pivotal Phase 2 trial for Danon disease.
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
[url="]Rocket Pharmaceuticals, Inc.[/url] (Rocket or the Company) (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic m
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (Rocket or the Company) (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today announced a positive clinical safety update regarding the initial three patients treated under the modified protocol for its global, pivotal Phase 2 trial of RP-A501 in Danon disease. Early safety has been promising with t.
